ABEONA THERAPEUTICS INC.
For the period ended Mar 9, 2026. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 9, 2026 · Filed Mar 9, 2026
Use the contents to explore the available documents and sections.
ABEO$4.17+6.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Indication
Indication
ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.